Physician profile
Mark J Korte
NPI 1821102849
$1,226.78
in general payments reported to CMS, 2019-2025
11 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.22 · 2020: $88.27 · 2021: $11.69 · 2023: $149 · 2024: $476 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,112.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $606.36 | 2021-2025 | |
| Pfizer INC. | $194.20 | 2019-2025 | |
| Novo Nordisk INC | $114.55 | 2023-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $101.98 | 2020-2024 | Zepbound |
| Phathom Pharmaceuticals, INC. | $69.93 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $26.27 | 2023 | Gemtesa |
| Glaxosmithkline, LLC. | $24.99 | 2023 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $24.42 | 2024 | Vaxneuvance, Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $23.87 | 2025 | Trintellix |
| Astellas Pharma US INC | $22.03 | 2023 | Veozah |
| Dexcom, INC. | $18.18 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Korte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.